Funding Supports Advancement of Obesity Program and Strategic Business Development Initiatives Advancement of novel next-generation MC4R long-acting peptides and oral small molecules IND applications planned for Q4 2025; clinical data expected H1 2026 Phase 1 SAD/MAD studies to include patients with hypothalamic obesity Ocular asset collaborations expected in Q2 and Q3 2025CRANBURY, N.J., May 7, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (the "Company" or "Palatin") (NYSE American: PTN), a biopharmac ...

Topical melanocortin therapy shows promise for treating glaucoma PL9588 lowers intraocular pressure (IOP) by increasing aqueous outflow Demonstrates neuroprotection independent of IOP reduction Supports continued development of PL9588 as a novel, dual-action glaucoma therapyCRANBURY, N.J., May 5, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company advancing innovative treatments targeting the melanocortin receptor system, today announced new preclinical data fo ...

Updated Phase 3 analyses position PL9643 as a potential first-in-class therapy achieving full symptom resolution in dry eye disease. Responder analyses demonstrated statistically significant symptom clearing (resolution) across multiple endpoints in patients treated with PL9643, compared to placebo. Six of 13 symptom endpoints showed a significantly higher percentage of patients in the PL9643 group achieving complete symptom resolution compared to placebo (p<0.05). This level of symptom clearing has not b ...

Co-administered bremelanotide + tirzepatide, bremelanotide alone, and tirzepatide alone arms showed improvement in appetite suppression, fullness, and satiety Bremelanotide matched or exceeded tirzepatide in appetite suppression Low-dose bremelanotide helped prevent appetite rebound after tirzepatide cessation CRANBURY, N.J., April 17, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the a ...

Six-month open-label study showed clinically meaningful improvements in kidney function and disease in patients with Type 2 diabetic nephropathy. 71% achieved a >30% reduction in UP/Cr, a key indicator of kidney damage. 71% demonstrated improved or stabilized eGFR, signaling preserved kidney function. 37.5% had increased urinary VEGF levels, suggesting better blood vessel support in the kidneys. 36% had reduced urinary synaptopodin losses, indicating healthier kidney cells and structure. CRANBURY, N.J., A ...

CRANBURY, N.J., March 31, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that its BMT-801 Phase 2 obesity co-administration study met its primary endpoint and was highly statistically significant. The Company reported positive topline data with co-administered melanocortin-4 receptor (MC4R) agonist bremelanotide plus glucago ...

Clinical Remission: Achieved in 33% of PL8177-treated patients versus 0% on placebo after eight weeks of treatment. Clinical Response (statistically significant): Demonstrated in 78% of PL8177-treated patients versus 33% on placebo after eight weeks of treatment (p<0.005). Symptomatic Remission: Achieved in 56% of PL8177-treated patients versus 33% on placebo after eight weeks of treatment. Safety and Tolerability: Excellent, with no adverse events. Licensing: Discussions advancing with multiple big pharma ...

Initiated IND-enabling toxicology program IND submission planned for 4Q25; Clinical data expected in 1H26 CRANBURY, N.J., March 25, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the US Food & Drug Administration (FDA) has granted "orphan drug" designation to PL7737, an oral treatment that activates the melanocortin-4 rece ...

Financial Data and Key Metrics Changes - For Q2 2025, Palatin Technologies did not record any product sales due to the completion of the sale of worldwide rights for female sexual dysfunction to CoSette Pharmaceuticals, resulting in gross product sales of $4.3 million and net product revenue of $2 million for Q2 2024 [6] - Total operating expenses for Q2 2025 were $2.6 million, net of a $2.5 million gain on the sale by lessee, compared to $0.9 million net of a $7.8 million gain for the same quarter in 2024 [6][7] - The net loss for Q2 2025 was $2.4 million, a decrease from a net loss of $7.8 million in Q2 2024, primarily driven by changes in fair values of warrant liabilities and the elimination of leasing net product revenue [8][9] - Cash and cash equivalents as of December 31, 2024, were $3.4 million, an increase from $2.4 million at September 30, 2024, but down from $9.5 million as of June 30, 2024 [10] Business Line Data and Key Metrics Changes - The company is focusing on its obesity and weight loss management portfolio, which includes both long-acting monoclonal 4 receptor selective peptide agonists and orally active small molecules [12][14] - The phase two signal detection study for BMP 801 has been completed, with top-line data expected later this month [12] Market Data and Key Metrics Changes - The market for pharmacological treatment of obesity is projected to exceed $100 billion annually, indicating significant growth potential for the company's products [20] Company Strategy and Development Direction - The company is concentrating its research and development efforts on melanocortin-4 receptor agonists, believing they will play a critical role in obesity treatment and weight loss management [21] - Palatin Technologies is actively engaged in discussions for out-licensing its programs and seeking strategic partnerships to enhance its market position [18][19] Management Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming data releases and the potential for significant advancements in obesity treatment [22][42] - The company is preparing for an exciting 2025, with expectations for substantial developments in its clinical programs [42] Other Important Information - The company is exploring opportunities in rare and orphan syndromic diseases related to melanocortin-4 receptor agonists, which could provide additional market opportunities [35][36] Q&A Session Summary Question: Focus on upcoming obesity data and benchmarks - Analyst inquired about the expected weight loss benchmarks in comparison to tirzepatide data and what would be considered a win for the study [24][25] Response: - Management clarified that they are looking for a clear signal rather than a specific percentage, focusing on the percentage of patients achieving clinically meaningful weight loss [26][27][30] Question: Additional indications beyond general weight loss - Analyst asked if there are other indications being considered for melanocortin-4 receptor agonists [34] Response: - Management acknowledged the potential for using these agonists in rare and orphan diseases, highlighting hypothalamic obesity as a significant market opportunity [35][36]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number: 001-15543 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 95-4078884 (Sta ...